Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma: A Prospective Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- CYP2B6
研究概览
简要总结
The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.
详细描述
All patients had their baseline viral indicators for HBV and HCV evaluated. Additionally, blood samples were taken for genotyping. All patients underwent evaluations of their kidney, liver, and alpha fetoprotein (AFP) functions, as well as their complete blood count (CBC), at both the baseline and follow-up appointments. To evaluate the efficacy of TACE, triple pelvic abdominal CT scans were performed both prior to and one month later. Using triphasic pelviabdominal CT, patients who achieved complete response (CR) were monitored for up to 13 months following chemotherapy in order to identify recurrence. Follow-up appointments were planned to identify patients responces or any negative effects.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •When diagnosing the patient with HCC, the guidelines provided by the American Association for the Study of Liver Diseases (AASLD) were adhered to.
- •Be above 20 years old.
- •Individuals with intact organs.
- •There is no cure for HCC in surgery, microwave treatment, or radiofrequency ablation.
排除标准
- •The patients refused to sign the formal consent.
- •Be more than 75 years old.
- •There is a notable case of portal vein thrombosis.
- •Spreads beyond the liver.
- •Encephalopathy of the liver.
- •Present sickness.
研究组 & 干预措施
HCC patients
Each of the patients was given Doxorubicin and followed up for one year.
干预措施: Doxorubicin (Drug)
结局指标
主要结局
CYP2B6
时间窗: 1 year
Genotyping
GSTP1
时间窗: 1 year
Genotyping
次要结局
未报告次要终点
研究者
Rehab Werida
Associate Professor
Damanhour University